Overexpression of Cdc25A phosphatase is often observed in cancer and results in poor prognosis. Cdc25A mainly dephosphorylates and thereby activates Cyclin-dependent kinase 2 and thus induces progression in the cell cycle from G 1 to S phase. Here, we demonstrate that the tumor suppressor p53 downregulates expression from the Cdc25A gene. In a p53-inducible cell system, Cdc25A expression on the mRNA and protein level is downregulated upon p53 expression. Promoter-reporter assays show that this regulation is dependent on the Cdc25A promoter. Mutant p53 fails to reduce Cdc25A transcription. In contrast to p53, neither p63 nor p73 can repress Cdc25A transcription. The Cdc25A promoter displays no p53 binding site, and p53 does not bind directly to the promoter DNA as shown by chromatin immunoprecipitation assays. Previously, the contribution of p53 to G 1 /S arrest has been mostly linked to activating the expression of the Cdk inhibitor p21 WAF1/CIP1 . By downregulating Cdc25A expression, p53 may impair transition from G 1 to S phase independently of p21 WAF1/CIP1 . Therefore, the data suggest that, as long as p53 is intact, Cdc25A transcriptional downregulation might play a role in cancer prevention. Oncogene (2007 Oncogene ( ) 26, 1949 Oncogene ( -1953 Oncogene ( . doi:10.1038 published online 25 September 2006 Keywords: p53; Cdc25A; G 1 to S transition; repression; tumor suppressor; transcription Cell cycle progression is mainly controlled by Cyclins and Cyclin-dependent kinases (Cdks), which successively act in G 1 to initiate the S phase and in G 2 to initiate mitosis. Proper control of Cyclin/Cdk activity ensures that the initiation of cell cycle events occurs only after a successful completion of the previous cycle. Cyclin/Cdk activity is regulated on several different levels, such as transcription of their genes, proteolysis, subcellular localization and binding of specific inhibitors (Obaya and Sedivy, 2002; Vermeulen et al., 2003) .
Another important level of regulation is reversible phosphorylation. Initially, Cyclin/Cdk complexes are kept in an inactive state by phosphorylation. The Myt1 and Wee1 kinases mediate the inactivation of Cdk1 and Cdk2 by phosphorylation of two sites in their ATP binding loop (Obaya and Sedivy, 2002) . Conversely, Cdc25 dual-specificity phosphatases catalyse cell cycle progression by dephosphorylating the same residues, thereby activating Cdks (Nilsson and Hoffmann, 2000) . In human cells, three Cdc25 family members -Cdc25A, Cdc25B and Cdc25C -have been characterized (Sadhu et al., 1990; Galaktionov and Beach, 1991; Nagata et al., 1991) . They are able to dephosphorylate both phosphoserines/threonines and phosphotyrosines on the same protein substrate. Cdc25B or Cdc25C regulate the transition from G 2 phase to mitosis through Cdk1 dephosphorylation (Millar et al., 1991; Strausfeld et al., 1994; Lammer et al., 1998) . Cdc25A mainly activates Cdk2 and thereby induces progression from G 1 to S phase. Microinjection of antibodies against Cdc25A arrests cells before the S phase, whereas ectopic expression of the phosphatase shortens the G 1 phase and accelerates cell cycle progression (Hoffmann et al., 1994; Jinno et al., 1994; Blomberg and Hoffmann, 1999; Sexl et al., 1999) . Emphasizing its role, Cdc25A has been described as an oncogene as the protein can induce cell transformation and is overexpressed in a wide variety of tumors (Galaktionov et al., 1995; Broggini et al., 2000; Cangi et al., 2000) . Recent evidence suggests that Cdc25A may also play a role in regulating the G 2 /M transition (Mailand et al., 2002; Chen et al., 2003) .
A principle factor involved in both G 1 and G 2 growth arrest as well as apoptosis regulation is the tumor suppressor protein p53. It can be activated by several stress conditions, such as DNA damage, hypoxia, heatshock, expression of viral and cellular oncogenes, as well as ionizing irradiation (Somasundaram, 2000) . p53 exerts its functions mainly as a transcription factor and binds to a specific DNA sequence activating transcription of target genes. One example of the numerous p53 transcriptional target genes is the Cdk inhibitor p21 WAF1/CIP1 (el-Deiry et al., 1993) . p21
binds to Cyclin/Cdk complexes, which leads to the inhibition of their kinase activity (Harper et al., 1995) . Transactivation of p21 WAF1/CIP1 and other p53 target genes like GADD45 and 14-3-3s is involved in mediating cell cycle arrest by p53 (Kastan et al., 1992; el-Deiry et al., 1994; Hermeking et al., 1997; Bunz et al., 1998) . In addition to activating transcription, p53 is also able to repress transcription from various promoters (Ho and Benchimol, 2003) . We have previously shown that the tumor suppressor protein p53 plays an important role in reducing the concentration of active Cyclin B/Cdk1 complex in the nucleus contributing to G 2 arrest. To this end, p53 can repress transcription of Cyclin B1, Cyclin B2 and Cdc25C genes (Krause et al., 2000 Manni et al., 2001) . Additionally, it has been shown that transcriptional repression by p53 is important for the promotion of apoptosis (Ho and Benchimol, 2003) .
In order to investigate whether p53 affects mRNA levels of the cell cycle regulator Cdc25A, we employed the colorectal adenocarcinoma DLD-1 cell line. DLD-1 cells are negative for functional p53 protein, but the DLD-1-tet-off-p53 cells were stably transfected with a system that permits (tet)-off-regulated expression of wild-type p53 (D53wt) or DNA-binding mutant p53 R175H (D53mut) (Yu et al., 1999; Krause et al., 2000) . This system allows selective induction of p53 protein expression by removal of doxycycline from the cell culture media (Figure 1b , left panel). In order to analyse primary changes in mRNA expression levels of p53 target genes without influences by major changes in cell cycle distribution or by apoptosis induction, we had tested earlier several different time periods for p53 induction. Nine hours after the removal of doxycycline from the cell culture medium, the p53 protein has just reached a level sufficient to influence its target genes (Krause et al., 2000; Dietz et al., 2002) . Induction of wild-type but not mutant p53 protein leads to an approximately four-fold downregulation of Cdc25A mRNA from the cellular gene 9 h after the removal of doxycycline compared to the non-induced state ( Figure 1a) . As described earlier, selective induction of wild-type p53 expression for 9 h neither leads to a relevant change in the cell cycle distribution nor to an elevated level of apoptotic cells (Krause et al., 2000; Dietz et al., 2002) . Therefore, the observed reduction of the Cdc25A mRNA level is not caused by cell cycle arrest or cells undergoing apoptosis.
With p63 and p73, two genes coding for proteins homologous to p53 have been identified (Kaghad et al., 1997; Schmale and Bamberger, 1997; Osada et al., 1998; Yang et al., 1998) . p53, p63 and p73 possess a similar domain structure and share substantial amino-acid identity in their DNA-binding domains. Nevertheless, p63 and p73 proteins do not represent classical tumor suppressors as their genes are rarely found mutated or deleted in tumors (Melino et al., 2003) . Furthermore, unlike p53 knockouts, p63 and p73 knockouts do not show enhanced cancer susceptibility but exhibit severe developmental abnormalities (Mills et al., 1999; Yang et al., 1999 Yang et al., , 2000 . p63 and p73 proteins are expressed in numerous splice variants making an analysis of their properties rather complex (Moll and Slade, 2004) . However, due to the structural homologies, some of the biological functions of p63 and p73 overlap with the role of p53. For example, p63 and p73 can activate transcription of some p53-responsive genes, such as p21 WAF1/CIP1 and Bax (Zhu et al., 1998; Katoh et al., 2000) . Therefore, we investigated the effect of p53 homologues on Cdc25A mRNA levels. The p53 family members included in this study were p73a, TAp63a, TAp63g, TA*p63a, TA*p63g, DNp63a and DNp63g. We used the same DLD-1-tet-off system to selectively induce expression of six different splice variants of p63 and p73a protein (Dietz et al., 2002) . Although the induction of protein expression of the p53 homologues are comparable to that of p53 (Figure 1b and data not shown), levels of Cdc25A mRNA only increased slightly after the induction of expression of all p53 homologues (Figure 1a and data not shown). Thus, in contrast to wild-type p53, the p73 and p63 subfamilies do not downregulate Cdc25A expression. However, as a control, we had shown earlier in the same experimental system that inducing the expression of p73a, TAp63a and TAp63g increases the expression of mRNA from the chromosomal p21 WAF1/CIP1 gene (Dietz et al., 2002) . This suggests that at least these three p53 family members are transcriptionally active, but do not influence Cdc25A mRNA levels.
As Cdc25A mRNA drops upon p53 induction we were interested if the protein level of Cdc25A is also affected by an increase in wild-type p53. Western blot analysis of total cell lysate prepared from DLD-1-tetoff-p53 cells, with or without the induction of wildtype p53 expression for 9 h, showed a significant decrease in Cdc25A protein expression (Figure 2 , upper Figure 1 Cdc25A mRNA levels transcribed from the chromosomal gene are downregulated upon expression of wild-type p53 but not after expression of p73a or TAp63a. DLD-1 colorectal cancer cells with (tet)-off-regulated wild-type transgenes for p53, p73a or TAp63a, respectively (Dietz et al., 2002) , were expressed from these genes by the removal of doxycycline. (a) Relative Cdc25A mRNA levels measured by real-time RT-PCR as described earlier (Krause et al., 2000 . Levels were standardized to GAPDH mRNA expression. Concentrations of mRNA from control DLD-1-tet-off cells in a medium containing doxycycline were set as the 100% reference. One representative experiment is shown. To elucidate whether the decrease in Cdc25A mRNA is dependent on the function of p53 as a regulator of transcription, we analysed the regulation of the Cdc25A promoter. To this end, we created a Cdc25A promoter construct by cloning a fragment of 906 nucleotides upstream of the translation start codon into a vector to drive the expression of a firefly luciferase reporter. The Cdc25A-wt-luci construct was transiently co-transfected with expression plasmids for human wild-type p53, a DNA-binding mutant of p53 (V143A) or a vector control in SaOS-2 cells, which are defective in p53 function. Wild-type p53 clearly downregulates the transcription from the Cdc25A promoter by approximately 20-fold (Figure 3) . Only a small reduction of reporter activity is seen upon expression of the p53 mutant.
To test the Cdc25A promoter for responsiveness to p73 and p63 we employed plasmids coding for wild-type p73a, p73b, TAp63a, TAp63g, TA*p63a, TA*p63g, DNp63a and DNp63g. We compared them to the respective DNA-binding deficient mutants. Neither p73a nor p73b nor any of the p63 splice variants tested are able to change transcription from the Cdc25A promoter significantly when compared to their transcriptionally inactive mutant forms (Figure 3 and data not shown). In control experiments, we found that p73a, p73b, TAp63g and TA*p63g are able to activate transcription from a p21 WAF1/CIP1 reporter (Dietz et al. (2002) and data not shown). This confirms that these four p53 family members are transcriptionally active. However, this activity does not alter transcription from the Cdc25A promoter.
Expression of Cdc25A phosphatase is repressed by wild-type p53 at the transcriptional level. A DNAbinding mutant of p53 fails to repress Cdc25A promoter activity. In order to examine if wild-type p53 can actually bind to the Cdc25A promoter we performed chromatin immunoprecipitation assays (ChIPs). Chromatin of DLD-1-tet-off-p53 cells before and after selective induction of p53 protein expression was crosslinked and immunoprecipitations were performed using antibody directed against p53. Promoter fragments of p21 WAF1/CIP1 and Cdc25A were amplified by PCR and a representative agarose gel of the PCR products is shown in Figure 4 . p53 bound to the p21 WAF1/CIP1 promoter both before and after selective induction of p53 protein expression. The presence of p53 before induction is due to the leakage of the tet-off-system employed. The absence of PCR amplification of the Cdc25A promoter after immunoprecipitation with anti-p53 antibody indicates that p53 does not bind to the Cdc25A promoter, neither before nor after selective induction of p53 protein expression. p53 likely represses Cdc25A indirectly by transactivating one or more p53 target genes. Such a mechanism should be considered as no direct binding of p53 to the Cdc25A promoter could be Figure 3 Cdc25A promoter is downregulated by p53 but not by TAp63a or p73a. The Cdc25A-promoter-reporter Cdc25A-wt-luci was co-transfected together with wild-type or mutant versions of p53, TAp63a or p73a expression plasmids in SaOS-2 cells according to the manufacturer's instructions. All experiments were standardized to Renilla luciferase activity as a control expressed from cotransfected pRL-null vector. Two hundred and fifty nanograms of Cdc25A-wt-luci plasmid were co-transfected with 25 ng of vector control or 25 ng of plasmids expressing wild-type or DNA-binding deficient mutant of p53, TAp63a or p73a. The vector control served as 100% standard. Firefly and Renilla luciferase activities were assayed with the Dual Luciferase Assay System (Promega, Mannheim, Germany) as suggested by the manufacturer. Figure 2 Expression of Cdc25A protein is downregulated after p53 induction. Western blot analysis of Cdc25A expression from total cell lysates and nuclear extracts, prepared from DLD-1-tetoff-p53 cells before or after induction of wild-type p53 expression, was carried out as described (Dietz et al., 2002; Tscho¨p et al., 2006) . Samples were analysed with antibodies directed against Cdc25A (F-6, 1:100, Santa Cruz Biotechnology, Santa Cruz, CA, USA), p53 (DO-1, 1:2000, Oncogene Merck, Darmstadt, Germany) or b-actin (AC-1, 1:5000, Sigma-Aldrich, Taufkirchen, Germany). Protein extracts from C33A cells untreated or transfected with a plasmid expressing Cdc25A protein served as a control.
Repression of Cdc25A by p53 K Rother et al observed (Figure 4) . Further experiments will elucidate the details of this mechanism.
In summary, our results reveal the cell cycle phosphatase Cdc25A as a new p53 target gene. This suggests that the tumor suppressor p53 may impair G 1 /S transition and thereby contribute to the prevention of uncontrolled cell growth. Thus, downregulation of Cdc25A could play a role in the cancer prevention as long as p53 is intact. Transcriptional repression of Cdc25A is neither observed with p63 nor with p73. This emphasizes different properties of the p53 family members in cell cycle control and points out the importance of p53 in the prevention of cancer by inducing cell cycle arrest by several independent pathways. WAF1/CIP1 promoters, before and after induction of wild-type p53 expression in DLD-1 cells, were carried out as described previously (Wasner et al., 2003a, b) using 1 Â 10 7 cells. Crosslinks were precipitated by 5 mg of anti-p53 mouse monoclonal antibody (DO-1, Oncogene) or without antibody (no Ab). The p21 WAF1/CIP1 promoter that has been shown to contain a p53 binding site served as a positive control. M denotes the marker lane with a 100 bp ladder (Fermentas, St Leon-Rot, Germany) giving the 500 bp band as the most prominent.
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